Skip to content

Samuel D Waksal

Chief Executive Officer at Graviton Bioscience.

Earliest Form D on file: Nov 2026

Filed Nov 13, 2026

Graviton Bioscience

ROCK2 inhibitors for fibrotic and autoimmune diseases

Biotech, New York NY

Signed as Chief Executive Officer

$5M

sold of $75M offered

Form D

LinkedIn

Network

At Graviton Bioscience

6 people